A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

This study is testing two new investigational drugs — BNT314 and BNT327 — in combination with standard chemotherapy for people with advanced colorectal cancer that has spread (metastatic). The study is testing whether these new drugs can help the immune system fight the cancer better than chemotherapy alone. **You may be eligible if...** - You have confirmed colorectal cancer that cannot be surgically removed and has a specific tumor profile (called MSS/pMMR) - You have measurable disease and are in good general health (ECOG 0–1) - You can provide a tumor tissue sample - Specific treatment history requirements apply depending on which part of the study you are entering (some require prior treatment, some do not) **You may NOT be eligible if...** - Your tumor is MSI-H (a specific tumor type that responds differently to immunotherapy) - You have received prior immunotherapy or certain other targeted therapies - You have significant heart disease, uncontrolled fluid around the lungs or heart, or active brain metastases - You have a history of autoimmune disease or have received an organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.